{"id":"high-dose-dexamethasone","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hyperglycemia"},{"rate":"15-25","effect":"Insomnia"},{"rate":"10-20","effect":"Mood changes (euphoria, anxiety)"},{"rate":"10-15","effect":"Hypertension"},{"rate":"variable","effect":"Immunosuppression/increased infection risk"},{"rate":"variable","effect":"Osteoporosis (with chronic use)"},{"rate":"5-10","effect":"Gastrointestinal upset"},{"rate":"5-10","effect":"Hypokalemia"}]},"_chembl":{"chemblId":"CHEMBL1697787","moleculeType":"Small molecule","molecularWeight":"528.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone acts as a glucocorticoid receptor agonist, translocating to the nucleus and modulating gene expression to decrease production of inflammatory mediators including TNF-α, IL-1, and IL-6. At high doses, it provides broad immunosuppression and anti-inflammatory effects, making it useful in acute inflammatory and autoimmune conditions. The drug also has mineralocorticoid activity at higher doses, affecting fluid and electrolyte balance.","oneSentence":"High-dose dexamethasone is a potent synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:40.366Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute inflammatory conditions"},{"name":"Autoimmune disorders"},{"name":"Cerebral edema"},{"name":"Severe allergic reactions"},{"name":"Adrenal insufficiency"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT05012033","phase":"","title":"Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2023-04-12","conditions":"Thyroid Eye Disease, Vasculitis, COPD Exacerbation Acute","enrollment":120},{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma","enrollment":48},{"nctId":"NCT07404709","phase":"PHASE1, PHASE2","title":"Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2026-02-28","conditions":"Sudden Hearing Loss, Extracellular Vesicles","enrollment":9},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT02405676","phase":"PHASE2, PHASE3","title":"BNHL-2015 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2015-01-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT02491632","phase":"PHASE2, PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":"Advanced Malignant Neoplasm, Fatigue, Metastatic Malignant Neoplasm","enrollment":90},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT06207123","phase":"PHASE1, PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":"Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":15},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT07469332","phase":"NA","title":"Comparison of the Effects of Moderate- and High-Dose Glucocorticoids on Postoperative Recovery","status":"NOT_YET_RECRUITING","sponsor":"Ankara City Hospital Bilkent","startDate":"2026-03-30","conditions":"Postoperative Recovery, PONV","enrollment":135},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT07100990","phase":"PHASE3","title":"Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-07-11","conditions":"Optic Neuritis, Myelitis, Myelitis, Transverse","enrollment":382},{"nctId":"NCT01572480","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-29","conditions":"Multiple Myeloma","enrollment":55},{"nctId":"NCT07432399","phase":"PHASE2","title":"Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2025-09-01","conditions":"Colon Cancer, Colorectal Cancer, Perioperative Immune Response","enrollment":100},{"nctId":"NCT04802356","phase":"PHASE2","title":"Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2021-04-07","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT07294677","phase":"PHASE1, PHASE2","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2026-03-17","conditions":"Leukemia, Lymphoma","enrollment":104},{"nctId":"NCT02659293","phase":"PHASE3","title":"Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2016-04-26","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT00343460","phase":"PHASE3","title":"APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2006-06","conditions":"Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":1428},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT06888817","phase":"PHASE3","title":"Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-06-19","conditions":"Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases","enrollment":408},{"nctId":"NCT07428369","phase":"PHASE2, PHASE3","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-06-05","conditions":"Multiple Myeloma (MM)","enrollment":1570},{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT03909412","phase":"PHASE1","title":"Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2019-10-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT07413809","phase":"PHASE3","title":"Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2025-10-31","conditions":"Multiple Myeloma","enrollment":92},{"nctId":"NCT03710603","phase":"PHASE3","title":"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2018-12-14","conditions":"Multiple Myeloma","enrollment":709},{"nctId":"NCT07388069","phase":"PHASE1, PHASE2","title":"Study of TN-001 Topical Eyedrops for Keratoconus","status":"ENROLLING_BY_INVITATION","sponsor":"TheiaNova Ltd.","startDate":"2025-12-23","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT06212336","phase":"PHASE2, PHASE3","title":"ISTH/ANRS 0409s INTEGRATE Lassa Fever Study","status":"RECRUITING","sponsor":"Irrua Specialist Teaching Hospital","startDate":"2025-05-02","conditions":"Lassa Fever","enrollment":1755},{"nctId":"NCT03617731","phase":"PHASE3","title":"Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2018-10-18","conditions":"Multiple Myeloma","enrollment":662},{"nctId":"NCT05180097","phase":"PHASE2","title":"Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2022-11-01","conditions":"Hodgkin Lymphoma","enrollment":84},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05023915","phase":"PHASE2","title":"A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shandong University","startDate":"2021-08-21","conditions":"Immune Thrombocytopenia","enrollment":106},{"nctId":"NCT07362914","phase":"PHASE3","title":"Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-07","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":"Multiple Myeloma","enrollment":729},{"nctId":"NCT06207305","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-30","conditions":"Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel","enrollment":39},{"nctId":"NCT07213375","phase":"PHASE2, PHASE3","title":"High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-09-01","conditions":"Analgetic, Lung Cancer (NSCLC), Video Assisted Thoracic Surgery (VATS)","enrollment":80},{"nctId":"NCT01208766","phase":"PHASE3","title":"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2011-01","conditions":"Multiple Myeloma","enrollment":1503},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT07315373","phase":"PHASE1","title":"Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-12-25","conditions":"Immune Thrombocytopenia","enrollment":60},{"nctId":"NCT06383572","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-26","conditions":"Lymphodepleting Chemotherapy, Myeloid Malignancies","enrollment":44},{"nctId":"NCT04653246","phase":"PHASE2","title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacob Laubach, MD","startDate":"2021-07-13","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant","enrollment":52},{"nctId":"NCT04068597","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","status":"RECRUITING","sponsor":"CellCentric Ltd.","startDate":"2019-08-09","conditions":"Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma","enrollment":250},{"nctId":"NCT02553460","phase":"PHASE1, PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT07169890","phase":"NA","title":"Clinical Insights Into Dextrose Phonophoresis on Mild to Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"MTI University","startDate":"2025-11-01","conditions":"Acne Vulgaris","enrollment":115},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT04817189","phase":"PHASE4","title":"Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2021-02-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":414},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT02937571","phase":"PHASE1, PHASE2","title":"High Dose Carfilzomib for Newly Diagnosed Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-10","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT06351644","phase":"PHASE1, PHASE2","title":"ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Adriana Rossi","startDate":"2024-10-02","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":2},{"nctId":"NCT05911321","phase":"PHASE2","title":"Isa-Pom-Dex in Elderly/Frail Subjects With RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-12-05","conditions":"Multiple Myeloma, Relapse, Refractory","enrollment":6},{"nctId":"NCT02252172","phase":"PHASE3","title":"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-02-16","conditions":"Multiple Myeloma","enrollment":737},{"nctId":"NCT04405167","phase":"PHASE1","title":"Tasquinimod for the Treatment of Relapsed or Refractory Myeloma","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT07206810","phase":"","title":"A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2018-08-01","conditions":"Myeloma","enrollment":419},{"nctId":"NCT05145400","phase":"PHASE2","title":"Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-02-18","conditions":"Multiple Myeloma, Cancer","enrollment":50},{"nctId":"NCT05745714","phase":"PHASE1, PHASE2","title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT07175415","phase":"PHASE1, PHASE2","title":"HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2026-10-01","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory","enrollment":42},{"nctId":"NCT05751044","phase":"PHASE1, PHASE2","title":"HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT07172685","phase":"NA","title":"Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-07-30","conditions":"Prostate Cancer","enrollment":116},{"nctId":"NCT03993912","phase":"PHASE3","title":"Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2019-10-17","conditions":"Multiple Myeloma","enrollment":294},{"nctId":"NCT07065968","phase":"PHASE2","title":"The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-19","conditions":"Immune Thrombocytopenia (ITP)","enrollment":132},{"nctId":"NCT01415882","phase":"PHASE2","title":"Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-31","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":165},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT05697809","phase":"PHASE2","title":"Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Oxular Limited","startDate":"2023-08-07","conditions":"Diabetic Macular Edema","enrollment":3},{"nctId":"NCT04545242","phase":"PHASE4","title":"Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions","status":"RECRUITING","sponsor":"Dr. Negrin University Hospital","startDate":"2021-07-06","conditions":"Acute Hypoxemic Respiratory Failure","enrollment":980},{"nctId":"NCT02195479","phase":"PHASE3","title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-09","conditions":"Multiple Myeloma","enrollment":706},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT06497738","phase":"","title":"A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-05-01","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT06176235","phase":"PHASE2","title":"Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia","status":"WITHDRAWN","sponsor":"Peking University People's Hospital","startDate":"2023-12-19","conditions":"Immune Thrombocytopenia","enrollment":""},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT06225466","phase":"PHASE4","title":"Muscle Relaxation for Pediatric Adenotonsillectomy","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-04-10","conditions":"Tonsillectomy","enrollment":172},{"nctId":"NCT07084753","phase":"NA","title":"Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy","status":"NOT_YET_RECRUITING","sponsor":"IVO JURISIC","startDate":"2025-07-30","conditions":"Obese Patients, Bariatric Surgical Pain, Bariatric Surgery (Sleeve Gastrectomy )","enrollment":36},{"nctId":"NCT04813653","phase":"PHASE1","title":"Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2021-04-18","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":3},{"nctId":"NCT07064889","phase":"PHASE2","title":"The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-07-30","conditions":"Immune Thrombocytopenia","enrollment":132},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT04775550","phase":"PHASE2","title":"DARA RVD For High Risk SMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Omar Nadeem, MD","startDate":"2021-03-08","conditions":"High-risk Smoldering Multiple Myeloma, Multiple Myeloma","enrollment":61},{"nctId":"NCT00869232","phase":"PHASE2","title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-10","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT05819541","phase":"PHASE2","title":"Treating Exacerbations of Asthma With Oral Montelukast in Children","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-10-20","conditions":"Status Asthmaticus","enrollment":90},{"nctId":"NCT05325593","phase":"PHASE3","title":"Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2022-12-02","conditions":"Primary Immune Thrombocytopenia","enrollment":129},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT07015021","phase":"NA","title":"The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-06-01","conditions":"Multiple Myeloma, Carfilzomib, Daratumumab","enrollment":72},{"nctId":"NCT05827549","phase":"PHASE2","title":"Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Ho Joon Im","startDate":"2024-04-04","conditions":"Acute Lymphoid Leukemia","enrollment":90},{"nctId":"NCT05136560","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis","status":"RECRUITING","sponsor":"CHA University","startDate":"2021-01-15","conditions":"Sepsis","enrollment":102},{"nctId":"NCT05608837","phase":"PHASE2","title":"Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Quan Dong Nguyen","startDate":"2023-05-26","conditions":"Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative","enrollment":28},{"nctId":"NCT04346654","phase":"PHASE2","title":"A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-10-09","conditions":"Immune Thrombocytopenia (ITP)","enrollment":26},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT02332850","phase":"PHASE1","title":"Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Martin, MD","startDate":"2015-01-21","conditions":"Multiple Myeloma","enrollment":83},{"nctId":"NCT03556332","phase":"PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-02","conditions":"Multiple Myeloma","enrollment":41},{"nctId":"NCT06307444","phase":"NA","title":"Ultrasound-Guided Erectro Spinae Plane Block Versus Stellate Ganglion Block for Patients With Upper Limb Acute Herpes Zoster Pain.","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-03-20","conditions":"Acute Herpes Zoster Pain Managment","enrollment":93},{"nctId":"NCT05469893","phase":"PHASE2","title":"Immuno-PRISM (PRecision Intervention Smoldering Myeloma)","status":"RECRUITING","sponsor":"Irene Ghobrial, MD","startDate":"2022-08-10","conditions":"High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma","enrollment":52},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CARDIAC ARREST"},{"count":1,"reaction":"CYTOKINE RELEASE SYNDROME"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"HEPATITIS ACUTE"},{"count":1,"reaction":"IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME"},{"count":1,"reaction":"MOTOR DYSFUNCTION"},{"count":1,"reaction":"MUSCULAR WEAKNESS"},{"count":1,"reaction":"MYELITIS"},{"count":1,"reaction":"PNEUMONIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Corticosteroid","Dexamethasone sodium phosphate"],"phase":"marketed","status":"active","brandName":"High-Dose Dexamethasone","genericName":"High-Dose Dexamethasone","companyName":"Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","companyId":"centro-de-educaci-n-medica-e-investigaciones-cl-nicas-norberto-quirno","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose dexamethasone is a potent synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Acute inflammatory conditions, Autoimmune disorders, Cerebral edema.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}